These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19413577)

  • 1. Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.
    Miller TR; Milicic I; Bauch J; Du J; Surber B; Browman KE; Marsh K; Cowart M; Brioni JD; Esbenshade TA
    Br J Pharmacol; 2009 May; 157(1):139-49. PubMed ID: 19413577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo receptor occupancy assay of histamine H₃ receptor antagonist in rats using non-radiolabeled tracer.
    Nirogi R; Kandikere V; Bhyrapuneni G; Muddana N; Saralaya R; Ponnamaneni RK; Manoharan AK
    J Pharmacol Toxicol Methods; 2012; 65(3):115-21. PubMed ID: 22487318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
    Esbenshade TA; Browman KE; Miller TR; Krueger KM; Komater-Roderwald V; Zhang M; Fox GB; Rueter L; Robb HM; Radek RJ; Drescher KU; Fey TA; Bitner RS; Marsh K; Polakowski JS; Zhao C; Cowart MD; Hancock AA; Sullivan JP; Brioni JD
    J Pharmacol Exp Ther; 2012 Oct; 343(1):233-45. PubMed ID: 22815533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
    Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
    J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
    Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
    Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain.
    Jansen FP; Wu TS; Voss HP; Steinbusch HW; Vollinga RC; Rademaker B; Bast A; Timmerman H
    Br J Pharmacol; 1994 Oct; 113(2):355-62. PubMed ID: 7834183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the specific binding of the histamine H3 receptor antagonist radioligand [3H]GR168320.
    Brown JD; O'Shaughnessy CT; Kilpatrick GJ; Scopes DI; Beswick P; Clitherow JW; Barnes JC
    Eur J Pharmacol; 1996 Sep; 311(2-3):305-10. PubMed ID: 8891613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain histamine H3 receptors in rats with portacaval anastomosis: in vitro and in vivo studies.
    Lozeva V; Attila M; Anttila E; Laitinen K; Hippeläinen M; Tuomisto L
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):574-81. PubMed ID: 9840427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Potent and Selective Histamine H
    Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
    J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of low level histamine H3 receptor occupancy by autoradiography.
    Le S; Finn JP; Larijani ME; Marino MJ; Schaffhauser H
    J Neurosci Methods; 2009 Dec; 185(1):70-5. PubMed ID: 19765611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]-thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex.
    Alves-Rodrigues A; Leurs R; Wu TS; Prell GD; Foged C; Timmerman H
    Br J Pharmacol; 1996 Aug; 118(8):2045-52. PubMed ID: 8864541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects.
    Jucaite A; Takano A; Boström E; Jostell KG; Stenkrona P; Halldin C; Segerdahl M; Nyberg S
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1231-9. PubMed ID: 23217964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
    Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
    J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranes.
    Harper EA; Shankley NP; Black JW
    Br J Pharmacol; 1999 Oct; 128(4):881-90. PubMed ID: 10556922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.
    Medhurst AD; Roberts JC; Lee J; Chen CP; Brown SH; Roman S; Lai MK
    Br J Pharmacol; 2009 May; 157(1):130-8. PubMed ID: 19222483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities.
    Raddatz R; Hudkins RL; Mathiasen JR; Gruner JA; Flood DG; Aimone LD; Le S; Schaffhauser H; Duzic E; Gasior M; Bozyczko-Coyne D; Marino MJ; Ator MA; Bacon ER; Mallamo JP; Williams M
    J Pharmacol Exp Ther; 2012 Jan; 340(1):124-33. PubMed ID: 22001260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H
    Riddy DM; Cook AE; Shackleford DM; Pierce TL; Mocaer E; Mannoury la Cour C; Sors A; Charman WN; Summers RJ; Sexton PM; Christopoulos A; Langmead CJ
    Neuropharmacology; 2019 Jan; 144():244-255. PubMed ID: 30359639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat.
    Able SL; Fish RL; Bye H; Booth L; Logan YR; Nathaniel C; Hayter P; Katugampola SD
    Br J Pharmacol; 2011 Jan; 162(2):405-14. PubMed ID: 20840537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.